- The US Food and Drug Administration has accepted for priority review US-based biopharmaceutical company Alexion Pharmaceuticals, Inc.'s (NASDAQ: ALXN) supplemental Biologics License Application for Ultomiris (ravulizumab-cwvz), the company's long-acting C5 complement inhibitor, for the treatment of people with atypical
hemolytic uremic syndrome in order to inhibit complement-mediated thrombotic microangiopathy, the company said.
Atypical
hemolytic uremic syndrome (aHUS) is a complement-mediated disease characterized by hemolytic anemia, thrombocytopenia and acute kidney injury.
"There is a clinically important chance of recovery in patients on dialysis with vasculitis, ischemic kidney failure, and
hemolytic uremic syndrome, which should be considered when planning kidney transplantation in these children," the authors write.
Long-term renal prognosis of diarrhea-associated
hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.
Virulence factors for
hemolytic uremic syndrome, Denmark.
Fakhouri et al., "Atypical
hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: improving Global Outcomes" (KDIGO) Controversies Conference," Kidney International, vol.
Atypical
Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.
Community outbreak of
hemolytic uremic syndrome attributable to Escherichia coli O111:NM--South Australia 1995.
Hemolytic uremic syndrome (HUS) is a rare disease characterized by thrombocytopenia and acute renal failure.
But just a few hours later a match was found and Saad, from Small Heath, became the first person in the world with aHUS - Atypical
hemolytic uremic syndrome - to undergo that type of surgery.
Atypical
hemolytic uremic syndrome is a triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure not associated with diarrhea.
- Atypical
Hemolytic Uremic Syndrome (Nondiarrhea- Associated
Hemolytic Uremic Syndrome) - Pipeline Review, H2 2015
